Product Description
an Engineered FGF21 Variant
Mechanisms of Action: FGF21 Analogue
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01869959 |
I1K-MC-GLUG | P1 |
Completed |
Type 2 Diabetes |
2009-06-01 |
2019-03-19 |
Treatments |
|
NCT00481117 |
I1K-MC-GLUD | P1 |
Completed |
Type 2 Diabetes |
None |
2019-03-21 |
Treatments |